In addition to BRAF, there is a gene called MEK that may be a factor in your diagnosis and treatment.
The MEK gene works together with BRAF, so your oncologist may add MEK inhibitors to your treatment plan. These drugs are called trametinib (brand name Mekinist) and cobimetinib (Cotellic), which have both been shown to shrink some melanomas that are associated with BRAF mutations.
The American Cancer Society notes that a common approach is to combine a MEK inhibitor with a BRAF inhibitor. This seems to shrink tumors for a longer period of time, compared to either drug used on its own. But keep in mind your treatment plan will be unique to you, based on what you and your doctor decide as the best course of action.